VisEn's molecular imaging technology platforms enable revolutionary imaging of key disease states, activities and processes both in animals and humans. These platforms provide entirely new opportunities in drug discovery and development in disease characterization, drug compound evaluation, and therapeutic course determination and management. Through defined applications of these molecular imaging technologies, researchers and clinicians are able to detect diseases earlier, understand diseases better, evaluate drug therapies and determine therapeutic courses of action -- all in real time. Flagship’s investment in VisEn began in 2005, and Managing Partner Ed Kania is Chairman of the company’s Board of Directors.

www.visenmedical.com